Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center.
1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
D M
DM
Stephens
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
A S
AS
Ruppert
1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
J A
JA
Jones
1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
J
J
Woyach
1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
K
K
Maddocks
1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
S M
SM
Jaglowski
1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
L A
LA
Andritsos
1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
J M
JM
Flynn
1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
M R
MR
Grever
Division of Hematopathology, Department of Pathology, The Ohio State University, Columbus, OH, USA.
G
G
Lozanski
1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA [3] Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
A J
AJ
Johnson
1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
N
N
Muthusamy
1] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA [2] Division of Cytogenetics, Department of Pathology, The Ohio State University, Columbus, OH, USA.
N A
NA
Heerema
1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA [3] Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
J C
JC
Byrd
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002872:Chromosome Deletion; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D011379:Prognosis; D015996:Survival Rate